The government, via the introduction of a new Drug Price Control Order (DPCO) in May 2013, already regulates the prices of 348 ‘essential drugs’ included in the country’s National List of Essential Medicines [1].
 
A panel convened by India’s health ministry met for the first time on 24 June 2014 to discuss adding more drugs to this list, thus subjecting them to price caps in order to improve affordability.

The move is hoped would improve affordable for ‘essential drugs’ in a country where 70% of the 1.2 billion people live on less than US$2 a day and less than 20% are covered by health insurance.

Generics companies in the country are increasingly being caught between a rock and a hard place, as companies requesting to stop production of ‘essential drugs’ have been denied by the National Pharmaceutical Pricing Authority (NPPA). The DPCO gives the NPPA the right to do this when the company’s market share of the drug is more than 1%.

Reference
1. GaBI Online - Generics and Biosimilars Initiative. India introduces new drug pricing control [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Aug 1]. Available from: www.gabionline.net/Policies-Legislation/India-introduces-new-drug-pricing-control

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2014 Pro Pharma Communications International. All Rights Reserved.